CelluTarget · Multifocal Motor Neuropathy · Treatments
✓ Standard of Care

Ezetimibe

1
Evidence entries
0
Clinical trials
1
High-confidence findings
Overview
Treatment Details
Mechanism of Action
Inhibits intestinal cholesterol absorption via the NPC1L1 transporter. Added to statin therapy when LDL-C targets are not achieved on maximum tolerated statin alone. Reduces LDL-C by an additional 15–25% on top of statin.
Dosing Notes
10 mg once daily, typically combined with statin.
Treatment Type
pharmaceutical
Clinical Evidence
What the Evidence Shows
Each finding below is linked to its primary source. Confidence levels reflect the quality and quantity of available evidence — not CelluTarget's endorsement of any treatment.
High: Supported by multiple robust studies or regulatory approval
Moderate: Supported by limited controlled studies or consistent case series
Low: Based on case reports, expert opinion, or early-phase data only
High ConfidenceSupported by multiple robust studies or regulatory approval
2026 ACC/AHA guideline: ezetimibe is recommended as add-on to statin when LDL-C target not achieved. The IMPROVE-IT trial demonstrated 6.4% additional MACE reduction vs statin alone.
Verified Jul 2026
Peer Reviewed
2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia
Published March 2026
View source ↗
Clinical Trials
Linked Trials
No clinical trials linked to this treatment yet.